APC. Advanced Proteome Therapeutics

Advanced Proteome Therapeutics Announces Non-Brokered Private Placement

Advanced Proteome Therapeutics Announces Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, British Columbia, Aug. 03, 2018 (GLOBE NEWSWIRE) --  Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8) is pleased to announce that, subject to the approval of the TSX Venture Exchange (the “Exchange”), it proposes to raise up to $400,000 through a non‑brokered private placement of up to 8,000,000 units at a price of $0.05 per unit.  Each unit will consist of one common share and one transferable common share purchase warrant of the Company, with each warrant exercisable for a period of two years from the date of closing at a price of $0.075 per share.

Finder’s fees may be payable in accordance with the policies of the Exchange. All securities issued in connection with the private placement are subject to a 4-month hold period in Canada.

The gross proceeds of the private placement will be used as follows:

Description:  Use of Proceeds
Research and development activities related to the Company’s site-selective linker technology for the development of antibody-drug conjugates: $280,000
General working capital: $120,000
Total: $400,000

The Company confirms that there is no material fact or material change about the Company that has not already been generally disclosed. 

ABOUT THE COMPANY:

Advanced Proteome Therapeutics Corporation is developing a proprietary technology to directly target cancerous tumors and avoid destroying normal cells. This type of agent is capable of greater potency, higher specificity, and lower toxicity than other therapies that can also attack healthy cells.  Advanced Proteome is working to streamline the process by which these agents are prepared, which to date, has been extremely cumbersome, limiting their potential.  

FOR FURTHER INFORMATION PLEASE CONTACT:

Advanced Proteome Therapeutics Corporation

William John (Bill) Dickie

President and Chief Executive Officer

Tel: 613.852.3217

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities referred to in this news release have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent U.S. registration or an applicable exemption from the U.S. registration requirements.

This news release does not constitute an offer for sale of securities for sale, nor a solicitation for offers to buy any securities.  Any public offering of securities in the United States must be made by means of a prospectus containing detailed information about the company and management, as well as financial statements.

EN
03/08/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Advanced Proteome Therapeutics

 PRESS RELEASE

Advanced Proteome Therapeutics Reports Positive Results and Advances C...

Advanced Proteome Therapeutics Reports Positive Results and Advances Collaboration with Heidelberg Pharma VANCOUVER, British Columbia , Nov. 14, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to announce very positive results from animal studies in collaboration with Heidelberg Pharma. Antibody–drug conjugates (ADCs) are an emerging class of therapeutic agents with the potential to revolutionize current treatment strategies and regimens to fight cancer. The combination of APC's proprietary site-selective pro...

 PRESS RELEASE

Advanced Proteome Therapeutics Reports Progress on Collaboration with ...

Advanced Proteome Therapeutics Reports Progress on Collaboration with Noria Pharmaceuticals VANCOUVER, British Columbia, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to announce the successful completion of the first phase of the Collaboration of APC with Noria Pharmaceuticals Inc. in the rapidly growing and dynamic field of antibody radioisotope conjugates which is expected to have a major impact in the fight against cancer. APC has succeeded in creating a construct using its proprietary, site-se...

 PRESS RELEASE

APC Comments on Favorable Results in Initial Animal Studies

APC Comments on Favorable Results in Initial Animal Studies VANCOUVER, British Columbia, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to report favorable results in initial animal studies. Antibody–drug conjugates (ADCs) are an emerging class of therapeutic agents with the potential to revolutionize current treatment strategies and regimens. The combination of APC's proprietary site-selective protein modification technology and Heidelberg Pharma's proprietary ATAC technology, featuring the mushroo...

 PRESS RELEASE

Advanced Proteome Therapeutics Announces Progress on Antibody-Radioiso...

Advanced Proteome Therapeutics Announces Progress on Antibody-Radioisotope Conjugate Initiative VANCOUVER, British Columbia, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to report significant progress in applying the Company’s site-selective linker technology to advance the rapidly growing field of antibody-radioisotope conjugates. APC has initiated a program to create well-defined, chemically controlled constructs that are expected to display higher selectivity and efficiency than has previously...

 PRESS RELEASE

Advanced Proteome Therapeutics Provides Overview of Current Activities...

Advanced Proteome Therapeutics Provides Overview of Current Activities and Strategic Objectives VANCOUVER, British Columbia, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to provide an overview of current projects prior to more detailed news releases that will be disclosed shortly. Radioimmunoconjugates APC’s site-selective technology is being employed in the emergent field of radioimmunoconjugates (radioactive substances that can carry radiation directly to cancer cells.) These conjugates are ma...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch